Table 1. PV-specific and control iPSC lines used in this study.
iPSC clone | Donor | JAK2 WT allele |
JAK2 V617F allele |
---|---|---|---|
BC1 | Healthy donor | 2 | 0 |
TNC1 | Sickle cell anemia | 2 | 0 |
iPV183 | PV patient #1 | 1 | 1 |
PVB1.11 | PV patient #2 | 2 | 0 |
PVB1.15 | 2 | 0 | |
PVB1.4 | 0 | 2 | |
PVB1.18 | 0 | 2 |
A panel of iPSCs derived from healthy donors and PV patients were used for this study. In addition to a healthy donor- and a sickle cell anemia patient-derived iPSCs, two clones generated from a PV patient’s blood cells also contained only wild-type JAK2 alleles (WT/WT). iPSC clones with homozygous JAK2 V617F mutation (V617F/V617F) were derived from the same PV patient. iPSCs with heterozygous JAK2 (WT/V617F) were derived from a separate PV patient in a previous study [33].
Abbreviations: iPSC, induced pluripotent stem cell; PV, polycythemia vera.